布罗鲁单抗玻璃体腔注射后视网膜血管炎与眼内炎症
诊断平均发生于注射后30天,平均视力从0.426 logMAR降至诊断时0.981 logMAR(P=0.008),随访25天后为0.833 logMAR(P=0.033)。
要点
- 布罗鲁单抗注射后视网膜血管炎和眼内炎症平均于30天诊断,可伴严重视力下降。
- 眼底表现包括视网膜动脉鞘化、节段性中断、无灌注、棉絮斑和Kyrieleis斑等。
- 荧光素血管造影可见动脉充盈延迟、无灌注和渗漏,需高度怀疑以免漏诊。
核心结论
- 布罗鲁单抗玻璃体腔注射后视网膜血管炎和眼内炎症以大小视网膜动脉不同程度闭塞和静脉周围异常为特征。
- 病变范围可从周边血管炎到视神经或黄斑周围大动脉闭塞,导致严重视力丧失。
研究设计与样本
- 研究对象为接受布罗鲁单抗6 mg/0.05 ml玻璃体腔注射治疗新生血管性年龄相关性黄斑变性的患眼。
主要发现
- 患眼既往抗VEGF玻璃体腔注射次数范围为2至80次。
- 视网膜血管炎和眼内炎症于布罗鲁单抗注射后平均30天诊断。
- 布罗鲁单抗注射前平均视力为0.426 logMAR(Snellen等效20/53),诊断视网膜血管炎时平均视力为0.981 logMAR(Snellen等效20/191,范围20/25-20/1600;P=0.008)。
- 所有患眼均显示眼内炎症,伴局灶或长节段鞘化、大小视网膜动脉不连续、硬化动脉、无灌注区、棉絮斑、Kyrieleis斑、静脉管径不规则伴扩张和硬化段、静脉周围出血和静脉炎灶等不同组合。
- 荧光素血管造影显示视网膜动脉充盈延迟、视网膜血管无灌注及受累血管和视神经的染料渗漏。
关键数值与推荐
- 2例患者全身栓塞病因评估无阳性发现,3例患者葡萄膜炎实验室评估阴性。
- 治疗包括全身、玻璃体腔和局部糖皮质激素的不同组合,2眼行玻璃体切割术但视力无改善。
- 平均随访25天后平均视力为0.833 logMAR(Snellen等效20/136),较基线下降(P=0.033)。
临床怎么用
- 布罗鲁单抗注射后出现眼内炎症或视力下降时应高度怀疑视网膜血管炎,因玻璃体细胞可能遮挡眼底细节。
- 诊断需结合眼底检查和荧光素血管造影评估视网膜动脉闭塞、无灌注和渗漏。
- 治疗可采用全身、玻璃体腔和局部糖皮质激素等不同组合,但部分患眼视力预后仍差。
局限性
- 随访时间短,平均随访25天。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate features and outcomes of eyes with retinal vasculitis and intraocular inflammation (IOI) after intravitreal injection (IVI) of brolucizumab 6 mg/0.05 ml for treatment of neovascular age-related macular degeneration. DESIGN: Retrospective case series. PARTICIPANTS: Fifteen eyes from 12 patients identified from 10 United States centers. METHODS: Review of patient demographics, ophthalmologic examination results, and retinal imaging findings. MAIN OUTCOME MEASURES: Baseline and follow-up visual acuity (VA), prior anti-vascular endothelial growth factor (VEGF) injections, clinical presentation, retinal findings, fluorescein angiography results, and treatment strategies. RESULTS: The number of previous anti-VEGF IVIs ranged between 2 and 80 in the affected eye before switching to brolucizumab. Retinal vasculitis and IOI were diagnosed at a mean of 30 days after brolucizumab IVI. Mean VA before brolucizumab IVI was 0.426 logarithm of the minimum angle of resolution (logMAR; Snellen equivalent, 20/53) and VA at diagnosis of retinal vasculitis was 0.981 logMAR (Snellen equivalent, 20/191; range, 20/25-20/1600; P = 0.008). All affected eyes showed IOI with variable combinations of focal or elongated segmental sheathing and discontinuity of small and large retinal arteries, sclerotic arteries, regions of vascular nonperfusion, cotton-wool spots, Kyrieleis plaques, irregular venous caliber with dilated and sclerotic segments, perivenular hemorrhages, and foci of phlebitis. Fluorescein angiography revealed delayed retinal arterial filling, retinal vascular nonperfusion, and variable dye leakage from affected vessels and the optic nerve. Systemic evaluation for embolic causes was unrevealing in 2 patients, and 3 patients showed negative laboratory assessment for uveitis. Treatment consisted of various combinations of corticosteroids (systemic, intravitreal, and topical), and 2 eyes underwent vitrectomy without improvement in vision. After a mean follow-up of 25 days, mean VA was 0.833 logMAR (Snellen equivalent, 20/136), which was reduced compared with baseline (P = 0.033). CONCLUSIONS: Retinal vasculitis and IOI after brolucizumab IVI are characterized by variable occlusion of large or small retinal arteries, or both, and perivenular abnormalities. It may span from peripheral vasculitis to occlusion of large retinal arteries around the optic nerve or macula with severe vision loss. A high index of suspicion is required because vitreous cells may obscure visualization of retinal details.
引用
- Baumal CR, Spaide RF, Vajzovic L, et al. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology. 2020. PMID: 32344075. doi:10.1016/j.ophtha.2020.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。